ClinicalTrials.Veeva

Menu

Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care (DAISEA-ECG)

U

University of Montreal

Status

Not yet enrolling

Conditions

Structural Heart Disease
Primary Care Provider

Treatments

Device: DeepECG plateform diagnosis & recommendations

Study type

Interventional

Funder types

Other

Identifiers

NCT06637293
DAISEA-ECG

Details and patient eligibility

About

The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence.

The primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.

Full description

Mathematically, sensitivity is calculated as True Positive / (True Positive + False Negative), where True Positive represents correctly referred patients and false negatives represents patients who should have been referred but were not.

The secondary objectives include determining the rate of cardiovascular evaluation referrals before and after the intervention (implementation of the DeepECG platform), the individual characteristics of the intervention (PPV, NPV, and specificity), as well as evaluating the feasibility of implementing AI-based automatic ECG interpretation in primary care through surveys of family physicians and cardiologists.

PPV: Positive predictive value NPV: Negative predictive value

Enrollment

2,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Family Physicians or Nurse Practitioners

Family physicians or nurse practitioners (NPs) practicing in one of the participating FMGs.

Family physicians who have given their free and informed consent. Patients

Adult patients (18 years or older). Patients without follow-up in cardiology or internal medicine for cardiovascular issues (arrhythmia, heart failure, myocardial infarction, atherosclerotic coronary artery disease, valvular heart disease) or those who had a negative investigation in the past with no additional follow-up.

ECG

Any 12-lead ECG performed with the MUSE GE 360 machine. ECG of adequate technical quality for interpretation (otherwise, it will be automatically rejected by the platform).

-

Exclusion criteria

  • Family Physicians or Nurse Practitioners

Family physicians practicing exclusively in pediatrics (patients under 18 years old).

Family physicians unable to follow the project guidelines.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

2,000 participants in 2 patient groups

No DeepECG plateform diagnosis & recommendations
No Intervention group
DeepECG plateform diagnosis & recommendations
Experimental group
Treatment:
Device: DeepECG plateform diagnosis & recommendations

Trial contacts and locations

1

Loading...

Central trial contact

Robert Avram, MD; Marie-Gabrielle Lessard, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems